Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Azeliragon |
Synonyms | |
Therapy Description |
Azeliragon inhibits the interaction between receptor for advanced glycation end products (RAGE) and its ligands, potentially resulting in decreased tumor cell viability (PMID: 34763082). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Azeliragon | PF-04494700|TTP488 | Azeliragon inhibits the interaction between receptor for advanced glycation end products (RAGE) and its ligands, potentially resulting in decreased tumor cell viability (PMID: 34763082). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05766748 | Phase Ib/II | Azeliragon | Study of Effect of Azeliragon in Patients Refractory to First-Line Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT05986851 | Phase II | Azeliragon | Azeliragon in MGMT Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT05789589 | Phase Ib/II | Azeliragon + Methylprednisolone Azeliragon Azeliragon + Dexamethasone | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases (ADORATION) | Recruiting | USA | 0 |
NCT05635734 | Phase Ib/II | Azeliragon | Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma | Active, not recruiting | ESP | 0 |